TSHA Intrinsic Valuation and Fundamental Analysis - Taysha Gene Therapies Inc

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value for Taysha Gene Therapies Inc.

Do our valuations actually work? See backtest results .

Fundamental Analysis

What Taysha Gene Therapies Does

Biotechnology Health Care

Taysha Gene Therapies is a biotechnology company that develops gene therapies for serious genetic diseases that affect the central nervous system, especially rare disorders of the brain and spinal cord. Its work is centered on designing one-time treatments that try to address the root cause of disease by delivering a working copy of a gene into a patient’s cells.

Headquarters: United States of America US
Employees: 99
IPO date: Sep 24, 2020

Read the full company overview

How Taysha Gene Therapies makes money

Gene therapy development

Taysha Gene Therapies develops gene therapy treatments for rare nervous system diseases and advances them through research, testing, and clinical trials.

Customers: Patients with rare genetic neurological diseases, with hospitals and doctors using the therapies if they reach approval; in early stages, the company also works with research partners and regulators.
Revenue Model: The company does not mainly sell approved medicines today; it is built to earn money in the future from licensed or sold therapies, collaboration agreements, and eventual product sales if its treatments are approved.

View Company Overview